Non-cytochrome P450 enzymes involved in the oxidative metabolism of xenobiotics: Focus on the regulation of gene expression and enzyme activity
Introduction
Oxidative metabolism is the most common and important type of biotransformation in drug phase I metabolism, which includes oxidation, reduction, and hydrolysis. Cytochrome P450s (CYP450s) are responsible for the oxidation of more than 90% of marketed drugs (Williams et al., 2004). Therefore, comprehensive knowledge of the structure-metabolism relationship, inhibition, induction, and polymorphisms of CYP450s has been obtained through numerous studies. With this knowledge, scientists can design structures for novel drug candidates that avoid CYP450 metabolism to improve drug stability, gain favorable pharmacokinetic properties with suitable half-life and sufficient exposure, and prevent drug-drug interactions (de Groot, 2006).
However, the development of combinatorial chemistry and rational drug design has allowed an increasing number of drugs with novel structures to emerge in recent years that are metabolized independently by CYP450s. In our research, we found that cyanopyrrolidine dipeptidyl peptidase-4 (DPP-4) inhibitors, the epidermal growth factor receptor tyrosine kinase inhibitor-containing alkynyl group, the triazolopyridazine tyrosine-protein kinase c-Met inhibitor, oxazolidinone antibiotics, and drugs with an aliphatic carbon chain underwent non-P450-mediated metabolism (Diao et al., 2013; Kong et al., 2019; Lin, Xie, Gao, Chen, & Zhong, 2014; Meng et al., 2015; Xu et al., 2017). Also, the well-established metabolic stability screening system occasionally fails to identify the involvement of non-P450 enzymes. The best-known example of this phenomenon is the induction of nephrotoxicity by SGX523, a c-Met inhibitor (Diamond et al., 2010). Based on previous in vitro microsome metabolism results, rats and dogs were used in non-clinical toxicity studies. Both species lack the enzyme aldehyde oxidase (AOX) that is, however, present in humans and results in the formation of a major metabolite (2-quinolinone-SGX523) in humans but was minimally detected or not detected at all in the non-human preclinical studies carried out in rats and dogs. This metabolite could cause crystal nephropathy and obstructive renal failure in human patients due to its low water solubility and ease of precipitation in renal tubules. Another example is the development of Lu AF09535, a negative allosteric modulator of human metabotropic glutamate 5 receptors. In vitro preclinical studies failed to identify the main enzyme of AOX in the metabolism of Lu AF09535, and an unexpected low exposure of Lu AF09535 was observed in the first clinical trial in humans.
Establishing metabolic phenotyping and investigating factors that inhibit or induce metabolic enzyme(s) activity for a specific drug are essential steps during drug development. These steps facilitate selecting appropriate species for preclinical toxicity studies and accurate prediction of metabolite-mediated adverse effects and potential clinical drug interactions in humans. They also help eliminate inappropriate candidate compounds such as Lu AF09535 early in the process of drug development.
This review focuses on several common non-cytochrome P450 enzymes involved in the oxidative metabolism of xenobiotics, including flavin-containing monooxygenase (FMO), AOX, xanthine oxidoreductase (XOR), monoamine oxidase (MAO), alcohol dehydrogenase (ADH), and aldehyde dehydrogenase (ALDH). It summarizes the current knowledge concerning factors that influence the non-cytochrome P450 enzyme activities, such as species differences, inhibitors, inducers, and gene regulation. Genetic polymorphisms, while an important aspect, are beyond the scope of this review.
Section snippets
General overview
FMOs are a subfamily of class B external flavoprotein monooxygenases located in the endoplasmic reticulum membranes. The FMO-mediated reaction is initiated in the presence of NADPH where flavin adenine dinucleotide (FAD) obtains two electrons (FADH2) then is oxidized into peroxyflavin (FADH-OOH) by oxygen. In the presence of a soft nucleophilic substrate, one oxygen atom from peroxyflavin transfers to the substrate, and another oxygen atom leaves FADH-OH in the form of water (Fig. 1) (Ziegler,
General overview
AOX belongs to the xanthine oxidase (XO) family of molybdo-flavoenzymes and exists in the cellular cytosol. AOX catalyzes the oxidation of a broad range of endogenous and exogenous substances in the presence of oxygen and water. The molybdenum (Mo) center of AOX attacks the electron-deficient site of the substrate through a nucleophilic mechanism, and Mo (VI) is reduced to Mo (IV). The electron transfer via two Fe-S redox centers converts it into molecular oxygen. Subsequently, molecular oxygen
General overview
XOR is another sub-group in the molybdo-flavoenzyme family that has been widely researched for over 100 years. AOX evolved from the XOR family, and they have many similarities in terms of structure and mechanisms of action. XOR is not limited as a cytosolic enzyme, as it is also located on the outer surface of the cell membrane and is present in milk and the circulation system (Harrison, 2002). XOR exhibits two forms based on its different electron acceptors, including xanthine dehydrogenase
General overview
Monoamine oxidases A and B are flavoprotein monooxygenases located in the mitochondria's outer membrane, and a small fraction adjuvant to the microsomal fraction (Youdim, Edmondson, & Tipton, 2006). The two isoforms demonstrate a similarity of approximately 70% in their amino acid sequences and play a central role in the metabolism of monoamine neurotransmitters and exogenous drug oxidation, such as antidepressant sertraline and anti-migraine drug sumatriptan (Dixon, Park, & Tarbit, 1994;
General overview
Mammalian ADHs are cytosolic enzymes that belong to the medium-chain dehydrogenases/reductases (MDR) superfamily. The catalytic mechanism of ADH is depicted in Fig. 5. In addition to the most well-known ethanol oxidation process, ADH is also involved in some aspects of exogenous drug metabolism. The role of ADH in drug metabolism has been described in a newly published review (Di, Balesano, Jordan, & Shi, 2021), in which the catalytic mechanism, tissue distribution, species differences,
General overview
ALDHs are distributed in every subcellular organelle, including the cytosol, mitochondria, endoplasmic reticulum, and nucleus (Marchitti, Brocker, Stagos, & Vasiliou, 2008). In a typical ALDH-catalysis, the thiol of cysteine in the active site attacks the carbonyl carbon of aldehyde substrate through a nucleophilic reaction and forms an oxyanion thiohemiacetal intermediate. Hydride transfers from the carbon of the oxyanion thiohemiacetal intermediate to the cofactor NAD(P)+, forming the
Concluding remarks
This review summarizes the xenobiotic factors that influence the activities of non-CYP450 enzymes to understand better and evaluate non-CYP450-mediated potential drug interactions in drug development and applications. Non-CYP450 enzymes participate in the primary or secondary oxidative metabolism of xenobiotics or metabolic intermediates in the broad substrate spectrum, such as aldehyde, hydroxyl, heterocycle, and amines. These metabolic enzymes play different roles in the body. Generally, the
Declaration of Competing Interest
The authors declare that there are no conflicts of interest.
Acknowledgments
This research was financially supported by the National Natural Science Foundation of China [81573500].
Reference (358)
- et al.
Xanthine oxidase-derived reactive oxygen metabolites contribute to liver necrosis: Protection by 4-hydroxypyrazolo[3,4-d]pyrimidine
Biochimica et Biophysica Acta
(2001) Inter-strain variability in aldehyde oxidase activity in the mouse
Comparative Biochemistry and Physiology, Part C: Toxicology & Pharmacology
(2002)- et al.
Identification of enzymes responsible for dantrolene metabolism in the human liver: A clue to uncover the cause of liver injury
Biochemical Pharmacology
(2018) - et al.
Pathophysiology of circulating xanthine oxidoreductase: New emerging roles for a multi-tasking enzyme
Biochimica et Biophysica Acta
(2014) Molybdenum hydroxylases: Biological distribution and substrate-inhibitor specificity
Progress in Medicinal Chemistry
(1987)Monoamine oxidase (MAO) in human peripheral tissues
Neurotoxicology
(2004)- et al.
In vitro and in vivo inhibition of human flavin-containing monooxygenase form 3 (FMO3) in the presence of dietary indoles
Biochemical Pharmacology
(1999) - et al.
Flavin-containing monooxygenase-3: Induction by 3-methylcholanthrene and complex regulation by xenobiotic chemicals in hepatoma cells and mouse liver
Toxicology and Applied Pharmacology
(2010) - et al.
Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase
Biochemical and Biophysical Research Communications
(1984) - et al.
Interspecies differences in the metabolism of methotrexate: An insight into the active site differences between human and rabbit aldehyde oxidase
Biochemical Pharmacology
(2015)
Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450
Japanese Journal of Pharmacology
Testosterone-induced upregulation of miRNAs in the female mouse liver
Steroids
Screening of the inhibitory effect of xenobiotics on alcohol metabolism using S9 rat liver fractions
Toxicology In Vitro
Aldehyde dehydrogenase inhibitors for cancer therapeutics
Trends in Pharmacological Sciences
Design, synthesis characterization and biological evaluation of novel multi-isoform ALDH inhibitors as potential anticancer agents
European Journal of Medicinal Chemistry
Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver
Biochemical Pharmacology
Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde
Biochemical Pharmacology
Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics
Molecular & Cellular Proteomics
Regulation of mouse liver flavin-containing monooxygenases 1 and 3 by sex steroids
Archives of Biochemistry and Biophysics
The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG Island Methylator phenotype
Molecular Cell
Mechanism of induction of mouse kidney alcohol dehydrogenase by androgen. Androgen-induced stimulation of transcription of the Adh-1 gene
The Journal of Biological Chemistry
Monoamine oxidase type A: Differences in selectivity towards l-norepinephrine compared to serotonin
Biochemical Pharmacology
Designing better drugs: Predicting cytochrome P450 metabolism
Drug Discovery Today
Acyclovir-induced nephrotoxicity: The role of the acyclovir aldehyde metabolite
Translational Research
Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases. Comparison of human liver and kidney microsomes and mammalian enzymes
Biochemical Pharmacology
Structure and function of xanthine oxidoreductase: Where are we now?
Free Radical Biology & Medicine
Synthesis of new 7-oxycoumarin derivatives as potent and selective monoamine oxidase A inhibitors
Journal of Medicinal Chemistry
Characterization of brimonidine metabolism with rat, rabbit, dog, monkey and human liver fractions and rabbit liver aldehyde oxidase
Xenobiotica
Case report of extensive metabolism by aldehyde oxidase in humans: Pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans
Xenobiotica
Coordinated regulation of hepatic phase I and II drug-metabolizing genes and transporters using AhR-, CAR-, PXR-, PPARalpha-, and Nrf2-null mice
Drug Metabolism and Disposition
Revealing the moonlighting role of NADP in the structure of a flavin-containing monooxygenase
Proceedings of the National Academy of Sciences of the United States of America
The species distribution of xanthine oxidase
The Biochemical Journal
Tissue distribution, ontogeny, and regulation of aldehyde dehydrogenase (Aldh) enzymes mRNA by prototypical microsomal enzyme inducers in mice
Toxicological Sciences
Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: Low potential for active or toxic metabolites or for drug-drug interactions
Cancer Chemotherapy and Pharmacology
Cytochrome P450 2C8 and flavin-containing monooxygenases are involved in the metabolism of tazarotenic acid in humans
Drug Metabolism and Disposition
Novel roles for AhR and ARNT in the regulation of alcohol dehydrogenases in human hepatic cells
Archives of Toxicology
Nuclear cathepsin D enhances TRPS1 transcriptional repressor function to regulate cell cycle progression and transformation in human breast cancer cells
Oncotarget
Hepatic metabolism of MK-0457, a potent aurora kinase inhibitor: Interspecies comparison and role of human cytochrome P450 and flavin-containing monooxygenase
Drug Metabolism and Disposition
A novel aldehyde dehydrogenase-3 activator leads to adult salivary stem cell enrichment in vivo
Clinical Cancer Research
Inhibition of human aldehyde oxidase activity by diet-derived constituents: Structural influence, enzyme-ligand interactions, and clinical relevance
Drug Metabolism and Disposition
Xanthine oxidoreductase in cancer: More than a differentiation marker
Cancer Medicine
Xanthine oxidoreductase in drug metabolism: Beyond a role as a detoxifying enzyme
Current Medicinal Chemistry
Tamoxifen, an anticancer drug, is an activator of human aldehyde dehydrogenase 1A1
Proteins
The deamination of noradrenaline and 5-hydroxytryptamine by rat-brain and heart monoamine-oxidase and their inhibition by cimoxatone, toloxatone and Md-770222
Naunyn-Schmiedebergs Archives of Pharmacology
Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: Safinamide and coumarin analogs
Journal of Medicinal Chemistry
Human aldehyde dehydrogenase genes: Alternatively spliced transcriptional variants and their suggested nomenclature
Pharmacogenetics and Genomics
Effects upon in-vivo nicotine metabolism reveal functional variation in FMO3 associated with cigarette consumption
Pharmacogenetics and Genomics
Disposition and metabolism of GSK2251052 in humans: A novel boron-containing antibiotic
Drug Metabolism and Disposition
ALDH3A1 is overexpressed in a subset of hepatocellular carcinoma characterised by activation of the Wnt/ss-catenin pathway
Virchows Archiv
Role of flavin-containing monooxygenase in drug development
Expert Opinion on Drug Metabolism & Toxicology
Cited by (0)
- 1
Xiaoyan Pang, Chongzhuang Tang, and Runcong Guo contributed equally to this work.